Ardelyx, Inc.
$3.09-5.5%YTD-44.0%1Y-38.8%
Price updated 5h ago·X counts updated 5d ago
On X
The complete picture of $ARDX on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.
134X posts · last 7 days
Chatter Meter
1×
How loud $ARDX's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.
AI verdictAI analysisGenerated by AI from underlying data
TickerTalks' own read on what's driving $ARDX — fundamentals, momentum, or an event — and whether it agrees with the X crowd.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $ARDX.
Biotechnology
No material change from last week — mRNA oncology platform remains the structural driver.
What this means for $ARDX
Neutral — Commercial biotech with tenapanor approved to block phosphate absorption in dialysis patients with hyperphosphatemia.
Top industry ETF
$IBBiShares Biotechnology ETF
+17.9%YTD
+31.7%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-23.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-9.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
-8.7%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-2.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
3.2Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-38.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
91.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
1.4Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.07$-0.07-7.0%
Q1 2026Apr 30, 2026$-0.15$-0.13-15.4%
Q4 2025Feb 19, 2026$0.02$0.020.0%
Q3 2025Oct 30, 2025$-0.00$-0.06+93.3%
Next earningsThu, Oct 29·consensus EPS $-0.01
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$94.5M+27.5%94.9%-34.7%$-0.15$-32.3M
Q4 FY25$125.2M+7.8%90.6%4.1%$-0.00$20.6M
Q3 FY25$110.3M+12.3%95.6%4.2%$-0.00$209K
Q2 FY25$97.7M+33.4%86.7%-14.7%$-0.08$-26.0M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$488.7M$481.6M – $494.0M-$0.18-$0.24 – -$0.098
FY27$624.1M$573.3M – $747.4M$0.25$0.03 – $0.678
FY28$842.0M$655.9M – $951.2M$0.81$0.35 – $1.318
FY29$1.1B$991.5M – $1.2B$1.37$1.20 – $1.596
FY30$1.3B$1.1B – $1.4B$1.76$1.55 – $2.046
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.4%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-10.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-40.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatHigh float · 239.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.685-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
8-KPress release / Reg FDAug 68-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary
8-KMaterial debt obligationJul 28-K — Item 2.03: Material debt obligation
AI summary
8-KOfficer or director changeJun 178-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary
8-KPress release / Reg FDApr 308-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary
3New insider — initial holdingsApr 223
AI summary
+ 13 other (5 13Gs · 3 proxys · 2 10-Qs · 1 routine 8-K) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS LawARDX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ardelyx (ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026ROSEN, A TOP-RANKED LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDXKaplan Fox Encourages Ardelyx, Inc. (ARDX) Investors to Contact the Firm Before the Deadline on November 16, 2026 for a Leadership RoleBronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · top 1 · last 7 days